RXRX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

24.59M

+440.82%

-0.323

-38.98%

16.28M

+10.41%

-0.320

-36%

17.94M

-6.67%

-0.302

-26.22%

Estimates Revision

The market is revising Downward the revenue expectations for Recursion Pharmaceuticals, Inc. (RXRX) for FY2025, with the revenue forecasts being adjusted by -11.57% over the past three months. During the same period, the stock price has changed by -21.15%.

Revenue Estimates for FY2025

Revise Downward

-11.57%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.9%

In Past 3 Month

Stock Price

Go Down

-21.15%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast RXRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RXRX is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

2 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

8.00

Averages

8.00

High

8.00

Current: 0.000

Low

8.00

Averages

8.00

High

8.00

JPMorgan

Neutral -> Overweight

upgrade

$10 -> $11

2025-12-17

Reason

JPMorgan

Price Target

$10 -> $11

2025-12-17

upgrade

Neutral -> Overweight

Reason

JPMorgan upgraded Recursion Pharmaceuticals to Overweight from Neutral with a price target of $11, up from $10. The firm says the company's REC-4881 has shown "strong and durable" efficacy in familial adenomatous polyposis. REC-4881's addressable market is now broader than previously expected, creating blockbuster potential, the analyst tells investors in a research note. JPMorgan sees peak sales of over $1B and a 60% probability of success. In addition, Recursion's REC-617, a CDK7 inhibitor, has shown early anti-tumor activity in platinum-resistant ovarian cancer, says JPMorgan.

Morgan Stanley

Equal Weight

initiated

2025-07-03

Reason

Morgan Stanley

Price Target

2025-07-03

initiated

Equal Weight

Reason

Morgan Stanley assumed coverage of Recursion Pharmaceuticals with an Equal Weight rating and $5 price target. Recursion has faced volatility due to a combination of macroeconomic factors, underperformance on initial clinical results and uncertainty on valuation and revenue drivers, the analyst tells investors in a research note. The recent pipeline prioritization and stage of clinical development for the proprietary pipeline leaves several open questions on valuation, the analyst tells investors in a research note.

Morgan Stanley

Equal Weight

downgrade

$8 -> $5

2025-06-17

Reason

Morgan Stanley

Price Target

$8 -> $5

2025-06-17

downgrade

Equal Weight

Reason

Morgan Stanley lowered the firm's price target on Recursion Pharmaceuticals to $5 from $8 and keeps an Equal Weight rating on the shares. The firm revised its model following the company's recent pipeline prioritizations, cost reductions, 20% workforce reduction and updated cash burn guidance.

Morgan Stanley

Vikram Purohit

Hold

Maintains

$10 → $8

2025-04-10

Reason

Morgan Stanley

Vikram Purohit

Price Target

$10 → $8

2025-04-10

Maintains

Hold

Reason

Morgan Stanley lowered the firm's price target on Recursion Pharmaceuticals to $8 from $10 and keeps an Equal Weight rating on the shares. The firm updated its model based on commentary through Q4 earnings and following the recent opportunity it had to catch-up with management on the current status of the pipeline, the analyst tells investors.

Needham

Gil Blum

Strong Buy

Reiterates

$11

2025-04-08

Reason

Needham

Gil Blum

Price Target

$11

2025-04-08

Reiterates

Strong Buy

Reason

Leerink Partners

Mani Foroohar

Hold

Maintains

$7 → $6

2025-02-28

Reason

Leerink Partners

Mani Foroohar

Price Target

$7 → $6

2025-02-28

Maintains

Hold

Reason

Valuation Metrics

The current forward P/E ratio for Recursion Pharmaceuticals Inc (RXRX.O) is -3.38, compared to its 5-year average forward P/E of -7.39. For a more detailed relative valuation and DCF analysis to assess Recursion Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-7.39

Current PE

-3.38

Overvalued PE

-1.23

Undervalued PE

-13.56

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-6.37

Current EV/EBITDA

-2.84

Overvalued EV/EBITDA

0.87

Undervalued EV/EBITDA

-13.62

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

84.05

Current PS

27.49

Overvalued PS

220.61

Undervalued PS

-52.51

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

RXRX News & Events

Events Timeline

No data

News

3.5

01-01Fool

Recursion Pharmaceuticals Faces Challenge as Eli Lilly Plans Largest AI Supercomputer

3.5

01-01NASDAQ.COM

Recursion Pharmaceuticals Chases Clinical Wins as Eli Lilly Builds Largest AI Supercomputer

6.0

2025-12-31Yahoo Finance

Recursion Pharmaceuticals (RXRX) Upgraded to Overweight by JPMorgan with $11 Price Target

People Also Watch

Frequently Asked Questions

What is Recursion Pharmaceuticals Inc (RXRX) stock price today?

The current price of RXRX is 4.66 USD — it has decreased -0.85 % in the last trading day.

What is Recursion Pharmaceuticals Inc (RXRX)'s business?

Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.

What is the price predicton of RXRX Stock?

What is Recursion Pharmaceuticals Inc (RXRX)'s revenue for the last quarter?

Recursion Pharmaceuticals Inc revenue for the last quarter amounts to 5.18M USD, decreased -80.16 % YoY.

What is Recursion Pharmaceuticals Inc (RXRX)'s earnings per share (EPS) for the last quarter?

Recursion Pharmaceuticals Inc. EPS for the last quarter amounts to -0.36 USD, increased 5.88 % YoY.

What changes have occurred in the market's expectations for Recursion Pharmaceuticals Inc (RXRX)'s fundamentals?

How many employees does Recursion Pharmaceuticals Inc (RXRX). have?

Recursion Pharmaceuticals Inc (RXRX) has 840 emplpoyees as of January 10 2026.

What is Recursion Pharmaceuticals Inc (RXRX) market cap?

Today RXRX has the market capitalization of 2.43B USD.